Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of MK-3415A, MK-3415, and MK-6072 for prevention of recurrent Clostridium difficile infection
2011-004590-90Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of actoxumab + bezlotoxumab, actoxumab and bezlotoxumab in Clostridioides difficile colitis (CDI) (4 arms), sponsored by Merck & Co. Primary endpoint: Proportion of patients with Clostridium difficile infection recurrence. Started Nov 2011; status: completed.
02
Drugs
actoxumab + bezlotoxumabactoxumabbezlotoxumab
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2011-004590-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004590-90.